Novel anti-platelet therapy reduces risk of cardiac events in patients with history of heart attack
According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular ...
Aug 27, 2012
0
0